Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease

Physiology and Behavior

Volumn 98, Issue 1-2, 2009, Pages 130-138

  Luchtman, Dirk W ^a   Shao, Di ^a   Song, Cai ^a  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Behavior; Cytokines; Dosing regimen; Frontal cortex; Midbrain; Neurotransmission; Parkinson's disease (PD); Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; DISEASE MODEL; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; FRONTAL CORTEX; MALE; MESENCEPHALON; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN BRAIN LEVEL; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PRIORITY JOURNAL; ROTAROD TEST; SEROTONIN BRAIN LEVEL; SEROTONIN METABOLISM;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; NEOSTRIATUM; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE, SECONDARY; POSTURAL BALANCE; PROBENECID; URICOSURIC AGENTS;

EID: 67649506219     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2009.04.021     Document Type: Article

References (62)

1. Langston J.W. MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci 36 (1985) 201-206
2. Heikkila R.E., Cabbat F.S., Manzino L., and Duvoisin R.C. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice. Neuropharmacology 23 (1984) 711-713
3. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice. Neurosci Lett 58 (1985) 133-137
4. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
5. Sedelis M., Schwarting R.K., and Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125 (2001) 109-125
6. Meredith G.E., and Kang U.J. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 21 (2006) 1595-1606
7. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., et al. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis 14 (2003) 218-228
8. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76 (2001) 1265-1274
9. Crabbe J., Wahlsten D., and Dudek. Genetics of mouse behavior: interactions with laboratory environment. Science 284 (1999) 1670-1672
10. Vučković M.G., Wood R.I., Holschneider D.P., Abernathy A., Togasaki D.M., Smith A., et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 32 (2008) 319-327
11. Fredriksson A., Schröder N., Eriksson P., Izquierdo I., and Archer T. Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism. Relat Disord 7 (2001) 97-105
12. Rommelfanger K.S., and Weinshenker D. Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74 (2007) 177-190
13. Rozas G., Liste I., Guerra M.J., and Labandeira-Garcia J.L. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 245 (1998) 151-154
14. Miklossy J., Doudet D.D., Schwab C., Yu S., McGeer E.G., and McGeer P.L. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 197 (2006) 275-283
15. Kurkowska-Jastrzebska I., Wrońska A., Kohutnicka M., Członkowski A., and Członkowska A. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars) 59 (1999) 1-8
16. Baba Y., Kuroiwa A., Uitti R.J., Wszolek Z.K., and Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11 (2005) 493-498
17. Mount M.P., Lira A., Grimes D., Smith P.D., Faucher S., Slack R., et al. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27 (2007) 3328-3337
18. Nagatsu T., and Sawada M. Inflammatory process in Parkinson's disease: role of cytokines. Curr Pharm Des 11 (2005) 999-1016
19. Liu B., and Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304 (2003) 1-7
20. Nagatsu T., Mogi M., Ichinose H., and Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl 58 (2000) 143-151
21. Pattarini R., Smeyne R.J., and Morgan J.I. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience 145 (2007) 654-668
22. Teismann P., and Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318 (2004) 149-161
23. Dunn A.J., and Wang J. Cytokine effects on CNS biogenic amines. Cytokine effects on CNS biogenic amines. Neuroimmunomodulation 2 (1995) 319-328
24. Dunn A.J. Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 6 (2006) 52-68
25. Schiepers O.J., Wichers M.C., and Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol Psychiatry 29 (2005) 201-217
26. Meredith G.E., Totterdell S., Potashkin J.A., and Surmeier D.J. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 14 (2008) S112-S115
27. Petroske E., Meredith G.E., Callen S., Totterdell S., and Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106 (2001) 589-601
28. Lau Y.S., Trobough K.L., Crampton J.M., and Wilson J.A. Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen Pharmacol 21 (1990) 181-187
29. Fredriksson A., Gentsch C., and Archer T. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP treated mice. J Neural Transm Gen Sect 97 (1994) 197-209
30. Fredriksson A., Plaznik A., Sundström E., and Archer T. Effects of D1 and D2 agonists on spontaneous motor activity in MPTP treated mice. Pharmacol Toxicol 75 (1994) 36-41
31. Sonsalla P.K., and Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129 (1986) 339-345
32. Vitali R., and Clarke S. Improved rotorod performance and hyperactivity in mice deficient in a protein repair methyltransferase. Behav Brain Res 153 (2004) 129-141
33. Rozas G., and Labandeira Garcia J.L. Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res 749 (1997) 188-199
34. Hall C.S. Emotional behavior in the rat. 1. Defecation and urination as measures of individual differences in emotionality. J Comp Psychol 18 (1934) 385-403
35. Song C., Li X., Leonard B.E., and Horrobin D.F. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res 44 (2003) 1984-1991
36. Song C., Zhang X.Y., and Manku M. Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci 29 (2009) 14-22
37. Deacon R.M., Koros E., Bornemann K.D., and Rawlins J.N. Aged Tg2576 mice are impaired on social memory and open field habituation tests. Behav Brain Res 197 (2009) 466-468
38. Ogawa N., Hirose Y., Ohara S., Ono T., and Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50 (1985) 435-441
39. Yokoyama H., Kuroiwa H., Yano R., and Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 29 (2008) 293-301
40. Ookubo M., Yokoyama H., Takagi S., Kato H., and Araki T. Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice. Mol Cell Endocrinol 296 (2008) 87-93
41. Boger H.A., Middaugh L.D., Zaman V., Hoffer B., and Granholm A.C. Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene. Brain Res 1241 (2008) 18-28
42. Chalimoniuk M., and Langfort J. The effect of subchronic, intermittent L-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice. Neurochem Int 50 (2007) 821-833
43. Datta S.C., and Opp M.R. Lipopolysaccharide-induced increases in cytokines in discrete mouse brain regions are detectable using Luminex xMAP((R)) technology. J Neurosci Methods 75 (2008) 119-124
44. Farlow M.R., and Cummings J. A modern hypothesis: the distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dement Geriatr Cogn Disord 25 (2008) 301-308
45. Caballol N., Martí M.J., and Tolosa E. Cognitive dysfunction and dementia in Parkinson's disease. Mov Disord 22 (2007) S358-S366
46. Tariq M., Khan H.A., Moutaery K.A., and Deeb S.A. Dipyridamole potentiates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinsonism in mice. Parkinsonism Relat Disord 4 (1998) 43-50
47. Tariq M., Khan H.A., al Moutaery K., and al Deeb S.M. Effect of chronic administration of magnesium sulfate on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Pharmacol Toxicol 82 (1998) 218-222
48. Fernagut P.O., Diguet E., Bioulac B., and Tison F. MPTP potentiates 3 nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp Neurol 185 (2004) 47-62
49. Chia L.G., Ni D.R., Cheng L.J., Kuo J.S., Cheng F.C., and Dryhurst G. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice. Neurosci Lett 218 (1996) 67-71
50. Quinn L.P., Stean T.O., Chapman H., Brown M., Vidgeon-Hart M., Upton N., et al. Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. J Neurosci Methods 156 (2006) 218-227
51. Rabey J.M., and Burns R.S. Neurochemistry. In: Weiner W.J., and Factor S.A. (Eds). Parkinson's disease: diagnosis and clinical management (2002), Demos Medical Publishing, New York, New York 195-211
52. Gaspar P., Febvret A., and Colombo J. Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Exp Brain Res 96 (1993) 100-106
53. Mavridis M., Degryse A.D., Lategan A.J., Marien M.R., and Colpaert F.C. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41 (1991) 507-523
54. Bing G., Zhang Y., Watanabe Y., McEwen B.S., and Stone E.A. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 668 (1994) 261-265
55. Rommelfanger K.S., Weinshenker D., and Miller G.W. Reduced MPTP toxicity in noradrenaline transporter knockout mice. J Neurochem 91 (2004) 1116-1124
56. Rommelfanger K.S., and Weinshenker D. Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74 (2007) 177-190
57. Rommelfanger K.S., Edwards G.L., Freeman K.G., Liles L.C., Miller G.W., and Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci 104 (2007) 13804-13809
58. Espejo E.F., and Miñano J. Adrenergic hyperactivity and metanephrine excess in the nucleus accumbens after prefrontocortical dopamine depletion. J Neurophysiol 85 (2001) 1270-1274
59. Stam C.J., de Bruin J.P., van Haelst A.M., van der Gugten J., and Kalsbeek A. Influence of the mesocortical dopaminergic system on activity, food hoarding, social-agonistic behavior, and spatial delayed alternation in male rats. Behav Neurosci 103 (1989) 24-35
60. Henze C., Hartmann A., Lescot T., Hirsch E.C., and Michel P.P. Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor. J Neurochem 95 (2005) 1069-1077
61. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 29 (2009) 954-963
62. Song C., Merali Z., and Anisman H. Interaction of stress and cytokines interleukine-1, 2 and 6 at the nucleus accumbens; an in vivo microdialysis. Neuroscience 88 (1999) 23-836